SAM
NTLA icon

Smartleaf Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Smartleaf Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.3K Buy
627
+424
+209% +$5.4K ﹤0.01% 2468
2025
Q4 		$1.84K Buy
203
+104
+105% +$1.43K ﹤0.01% 3009
2025
Q3 		$1.68K Buy
99
+72
+267% +$887 ﹤0.01% 2652
2025
Q2 		$258 Sell
27
-23
-46% -$189 ﹤0.01% 2644
2025
Q1 		$403 Hold
50
– – ﹤0.01% 2729
2024
Q4 		$570 Sell
50
-366
-88% -$5.71K ﹤0.01% 2765
2024
Q3 		$8.74K Buy
416
+252
+154% +$5.81K ﹤0.01% 1838
2024
Q2 		$3.8K Buy
+164
New +$3.9K ﹤0.01% 1935

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Smartleaf Asset Management's NTLA Position: Q1 2026 in Review

Smartleaf Asset Management increased its Intellia Therapeutics (NTLA) stake by 209% in Q1 2026, buying an estimated $5.4K and bringing the position to 627 shares worth $7.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

Smartleaf Asset Management first reported a position in NTLA in Q2 2024 and has held it in 8 quarters since. The position peaked at $8.74K in Q3 2024. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Smartleaf Asset Management held 627 shares of Intellia Therapeutics worth $7.3K as of Q1 2026.
  • Smartleaf Asset Management bought 424 Intellia Therapeutics shares in Q1 2026, an estimated $5.4K.
  • Intellia Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2468 holding.
  • Smartleaf Asset Management first reported a position in Intellia Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Smartleaf Asset Management's Intellia Therapeutics position peaked at $8.74K in Q3 2024.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.